(USD) | Sep 2023 | Q/Q |
---|---|---|
Revenue | 181.8MM | -7% |
Operating Income | 16.5MM | -30% |
Operating Expenses | 165.3MM | - |
Net Income | - | - |
G&A | 8.1MM | -11% |
Amortization | 1MM | - |
Interest Expense | 22MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 1, 2024, after the market closes.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the signing of an agreement with the Hebrew University, which facilitate Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform (LPT-CBD) in accordance with FDA's Chemistry Manufacturing Control (CDC) Guidelin
Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 7,952,840 Units at a price of $0.25 per Unit (the "Offering Price") for aggregate gross proceeds of $1,988,210.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the following:
Summit Hotel Properties, Inc. (NYSE:INN) Q4 2023 Earnings Call Transcript February 29, 2024 Summit Hotel Properties, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. Welcome to the Summit Hotel Properties Q4 […]
Q4 2023 Summit Hotel Properties Inc Earnings Call
The headline numbers for Summit Hotel Properties (INN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the fourth quarter and full year ended December 31, 2023.
Innovative Industrial Properties (IIPR) delivered FFO and revenue surprises of 1.79% and 3.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company's pharmacokinetic study of its LPT-CBD platform in rabbits.